COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Status:
Completed
Trial end date:
2021-08-13
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing
its effect on the proportion of subjects that are alive without respiratory failure at Day
22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen,
intubation and mechanical ventilation, or ventilation with additional organ support (e.g.,
pressors, RRT, ECMO).